Bone Therapeutics' pivotal Ph III osteonecrosis trial with PREOB hits a new milestone

7 November 2013

Closely-held Belgian regenerative medicines company Bone Therapeutics says that its Phase III pivotal trial to treat osteonecrosis with its lead bone forming cell product PREOB is actively running in 30 European centers.

Bone Therapeutics obtained clearance from the competent authorities to launch the pivotal Phase III trial with PREOB in osteonecrosis in 2012. Today, 30 centres across Belgium, Germany, France and the Netherlands are active and ready to recruit patients to assess the safety and efficacy of PREOB in early stage osteonecrosis of the femoral head. Osteonecrosis is a rare disease affecting around 200,000 new patients each year in Europe and the USA. There is currently no treatment for osteonecrosis available.

First-in-class autologous osteoblastic/bone forming cell product

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK